COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Medicinal Chemistry Approaches to Tuberculosis and Trypanosomiasis - 1st Edition - ISBN: 9780128175569, 9780128175576

Medicinal Chemistry Approaches to Tuberculosis and Trypanosomiasis, Volume 52

1st Edition

Serial Volume Editor: Kelly Chibale
eBook ISBN: 9780128175576
Hardcover ISBN: 9780128175569
Imprint: Academic Press
Published Date: 6th September 2019
Page Count: 188
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Tuberculosis
Steven J. Berthel, Christopher B. Cooper and Nader P. Fotouhi
2. Antituberculosis agents: Beyond medicinal chemistry rules
Marco Pieroni
3. Development of MmpL3 inhibitors for tuberculosis treatment
Giovanna Poce, Sara Consalvi, Giulia Venditti, Cristina Scarpecci and Mariangela Biava
4. Inhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis
Andrew M. Thompson and William A. Denny
5. Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance
Nicolas Willand, Marion Flipo, Baptiste Villemagne, Alain Baulard and Benoit Deprez
6. Sustainable anti-trypanosomatid drugs: An aspirational goal for medicinal chemistry
Maria Laura Bolognesi


Some of the more recent efforts in tuberculosis (TB) and trypanosomiasis drug discovery from both Product Development Partnerships (PDPs) and academia are highlighted in this this volume. Drug discovery approaches include both target- and phenotypic whole cell screening- approaches. Regarding the latter, mechanism of action studies through target identification are also illustrated.

Key Features

  • Provides an overview of the status of some of the current novel compounds in development as well as new emerging treatment options targeting novel mechanisms of action
  • Identification of hits from phenotypic whole cell screening, followed by target identification
  • Strategies aimed at improving the efficacy of existing clinically used anti-TB drugs by taking advantage inhibitors of mycobacterial transcriptional regulators to boost the anti-tubercular activity, and circumvent acquired-resistance


Medicinal chemists, synthetic chemists, biologists, pharmacologists and clinicians


No. of pages:
© Academic Press 2019
6th September 2019
Academic Press
eBook ISBN:
Hardcover ISBN:

Ratings and Reviews

About the Serial Volume Editor

Kelly Chibale

Kelly Chibale

Kelly Chibale is a full Professor of Organic Chemistry at the University of Cape Town (UCT) where he holds the Neville Isdell Chair in African-centric Drug Discovery and Development. He is also a Full Member of the UCT Institute of Infectious Disease & Molecular Medicine, a Tier 1 South Africa Research Chair in Drug Discovery, founding Director of the South African Medical Research Council (SAMRC) Drug Discovery and Development Research Unit at UCT and the Founder and Director of the UCT Drug Discovery and Development Centre (H3D). Kelly obtained his PhD in Synthetic Organic Chemistry from the University of Cambridge in the UK (1989-1992). This was followed by postdoctoral stints at the University of Liverpool in the UK (1992-94) and at the Scripps Research Institute in the USA (1994-96). He was a Sandler Sabbatical Fellow at the University of California San Francisco (2002), a US Fulbright Senior Research Scholar at the University of Pennsylvania School of Medicine (2008) and a Visiting Professor at Pfizer in the UK (2008).

Affiliations and Expertise

University of Cape Town, South Africa